Only come out to play when share price gets down to 53/54 and the instos give Dave a ring "Dave, time for another announcement. Doesn't matter what as long as its excitingly positive'
Printable View
It's not specifically been discussed, but if there comes a time where some institutional investors aren't buying anymore of the stock (whether in the primary of secondary markets) it's because their portfolios are already overweight principally with this kind of investment.
I know of an insto that is strongly of the belief PEB will succeed, but cannot buy more of the stock because they are already overweight, and the focus is on ensuring the interests of their members are maintained. i.e. Maintaining a set portfolio risk level and not adding to it.
So my point is basically if there is a time in future when instos are not buying, its not for the exact same reason each time.
"Liquid biopsy' looks like the way forward, rather than invasive procedures. There is a mention of bladder cancer in the item. So the field is expaning very fast and PEB might well be overtaken.
'This week, at the humongous (20,000-plus attendee) annual meeting of the American Association for Cancer Research, there were no less than 130 presentations, “poster” sessions, and panels on liquid biopsy studies'
http://fortune.com/2017/04/04/brains...h-04-04-intro/
Yep, Pacific Edge needs to be weary of the competition coming up behind them like the technology of a Nucleix.
But as I've said before:
1) Who is Nucleix targeting in terms of markets? Is it the same medical professional group PEB is targeting? ie. US urologists
2) How far in the hoop-jumping cycle are Nucleix. Bar a favoritism route, they will have many a thing to tick off to catch up to the existing players. The road to profile, respect and credibility is a long non-linear one.
3) What is to say PEB aren't planning on the development of smarter methods of doing the tests, contrary to their CxBladder suite. They would be silly not to be surveying the new innovative approaches out there, and looking to capitalize on them in their own space.
4) The nearer competition to PEB remains the other tests they have outperformed in clinical trials, and the old methods the likes of PEB are trying to replace or compete with. UroVysion FISH will be fighting hard to remain one of the pre-eminent tests, and will hope the big customers PEB has got in board will give PEB a resounding 'no' at the 11th hour. We'll leave it to urologists and urological groups, when given all the new and old choices available, to make this call.
Did you say ''on board'' ?
Woops skid. I should have said 'on their books' or atleast something less inflammatory than "on board"... silly me.:eek2::p I'll give a trigger warning next time.